Integrating Recent Advances into the Management of HER2-Positive Breast Cancer

Each 1-hour session will include 2 topic modules focused on recent advances in the management of HER2-positive breast cancer. Each event will employ an identical format that will include the following elements:

• Discussion of Steering Committee Members’ Treatment Recommendations
• Review of Available Clinical Research Findings
• Integration of Interactive Audience Q&A Discussion

MODULE 1: Evolving Management of HER2-Positive Localized Breast Cancer

MODULE 2: Selection and Sequencing of Therapy for HER2-Positive Metastatic Breast Cancer

Each session will conclude with a 5-minute Q&A segment

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess available Phase III data with HER2-directed antibody-drug conjugate (ADC) therapy as a component of neoadjuvant therapy for patients with high-risk localized disease, and consider the potential clinical role of this novel treatment approach. 
• Evaluate current research evidence with HER2-directed ADC therapy for patients with HER2-positive localized breast cancer with residual disease after neoadjuvant treatment. 
• Appraise available clinical research data, current guideline recommendations, and best practices to guide the selection and sequencing of therapy for patients with HER2-positive metastatic breast cancer (mBC). 
• Review recently presented Phase III data with HER2-directed ADC therapy as a component of first-line and maintenance therapy, and consider the role of this newly approved strategy for patients with HER2-positive mBC. 
• Recognize available research findings with HER2-targeted tyrosine kinase inhibitors as a component of maintenance therapy, and reflect on the utility of this approach for patients with HER2-positive mBC. 
• Appreciate the biological rationale for and available research findings with CDK4/6 inhibition in combination with endocrine and anti-HER2 maintenance therapy for patients with HR-positive, HER2-positive mBC, and use this information to personalize treatment recommendations. 
• Design an optimal approach to the care of patients with HER2-positive breast cancer and CNS metastases, evaluating the implications of prior treatment exposure, symptomatology, extent and time to new onset of disease, and other factors. 
• Consider ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation. 

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology. 

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

Steering Committee — The following faculty reported relevant financial relationships with ineligible entities:

Dr Anders — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Elucida Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Caris Life Sciences, Elucida Oncology, G1 Therapeutics Inc, Incyclix Bio, Lilly, Merck, Nektar Therapeutics, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Tesaro, A GSK Company, Zion Pharma; Data and Safety Monitoring Boards/Committees: Roche Laboratories Inc; Nonrelevant Financial Relationships: Jones and Bartlett Publishing, UptoDate. Dr Borges — Advisory Committees: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Pfizer Inc; Consulting Agreements: Gilead Sciences Inc, Olema Oncology, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Merck, Olema Oncology, Pfizer Inc. Dr Brufsky — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, BriaCell, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc; Contracted Research: Agendia Inc; Stock Options/Stock — Public Companies: Celcuity; Stock OPTIONS — Private Companies: Ataraxis. Dr Krop — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck KGaA, Puma Biotechnology Inc, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP. Dr Mahtani — Consulting Agreements: Agendia Inc, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hologic Inc, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Stemline Therapeutics Inc; Contracted Research: Gilead Sciences Inc. Dr Modi — Advisory Committees: ALX Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, D3 Bio, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Lilly, Nuvation Bio Inc, Pfizer Inc, Seagen Inc; Contracted Research: ALX Oncology, AstraZeneca Pharmaceuticals LP, Avacta Therapeutics, BioNTech SE, BriaCell, D3 Bio, Daiichi Sankyo Inc, Duality Biologics, Genentech, a member of the Roche Group, Nuvation Bio Inc, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: ALX Oncology. Dr O’Shaughnessy — Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, RayzeBio, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC. Dr Rimawi — Advisory Committees: Tempus; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Stemline Therapeutics Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Greenwich LifeSciences Inc, Pfizer Inc, Stemline Therapeutics Inc.

Program Chair — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.